An In Sitro Assay to Predict Primary Resistance to PD-1 Blockade.
Sign Up to like & getrecommendations! Published in 2021 at "Trends in molecular medicine"
DOI: 10.1016/j.molmed.2021.01.006
Abstract: Immune check point inhibition (ICI) is a paradigm shift in oncology, but most patients treated with ICI will not respond to treatment. Thus, the need for predictive biomarkers for ICI is high. Dubuisson and colleagues… read more here.
Keywords: resistance blockade; predict primary; primary resistance; assay predict ... See more keywords
Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps9603
Abstract: TPS9603Background: A significant number of patients do not respond to PD-1/L1 blockade because there are no pre-existing tumor antigen-specific T-cells in their tumors ready to attack the cancer. W... read more here.
Keywords: resistance blockade; talimogene laherparepvec; laherparepvec vec; reversing resistance ... See more keywords
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.22690
Abstract: Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and its ligand (PD-L1), have received extensive attention in the past decade because of their dramatic clinical outcomes in advanced malignancies. However, both primary… read more here.
Keywords: pathway resistance; regulation pathway; resistance blockade; blockade ... See more keywords
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2020.00441
Abstract: Cancer immunotherapies targeting immune checkpoints such as programmed cell-death protein 1 (PD-1) and its ligand programmed cell-death 1 ligand 1 (PD-L1), are revolutionizing cancer treatment and transforming the practice of medical oncology. However, despite all… read more here.
Keywords: blockade immunotherapy; resistance blockade; resistance; oncology ... See more keywords
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13040663
Abstract: Simple Summary Immune checkpoint blockade targeting PD-1/PD-L1 has a promising therapeutic efficacy in different tumors, but a significant percentage of patients cannot benefit from this therapy due to primary and acquired resistance during treatment. This… read more here.
Keywords: immunotherapy; resistance blockade; blockade; resistance ... See more keywords